JP4938454B2 - 止血を促進するためのフィブリノゲン標的微粒子 - Google Patents

止血を促進するためのフィブリノゲン標的微粒子 Download PDF

Info

Publication number
JP4938454B2
JP4938454B2 JP2006530592A JP2006530592A JP4938454B2 JP 4938454 B2 JP4938454 B2 JP 4938454B2 JP 2006530592 A JP2006530592 A JP 2006530592A JP 2006530592 A JP2006530592 A JP 2006530592A JP 4938454 B2 JP4938454 B2 JP 4938454B2
Authority
JP
Japan
Prior art keywords
fibrinogen
platelet
product
peptide
platelets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006530592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507480A5 (enExample
JP2007507480A (ja
Inventor
アリソン ヘレナ グーデル，
サラ マーガレット テイラー，
Original Assignee
ヘモスタティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘモスタティクス リミテッド filed Critical ヘモスタティクス リミテッド
Publication of JP2007507480A publication Critical patent/JP2007507480A/ja
Publication of JP2007507480A5 publication Critical patent/JP2007507480A5/ja
Application granted granted Critical
Publication of JP4938454B2 publication Critical patent/JP4938454B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2006530592A 2003-10-07 2004-10-07 止血を促進するためのフィブリノゲン標的微粒子 Expired - Fee Related JP4938454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0323378.0A GB0323378D0 (en) 2003-10-07 2003-10-07 Therapeutic agent
GB0323378.0 2003-10-07
PCT/GB2004/004235 WO2005035002A1 (en) 2003-10-07 2004-10-07 Fibrinogen targetting microparticles for promoting haemostasie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011143587A Division JP2011184465A (ja) 2003-10-07 2011-06-28 止血を促進するためのフィブリノゲン標的微粒子

Publications (3)

Publication Number Publication Date
JP2007507480A JP2007507480A (ja) 2007-03-29
JP2007507480A5 JP2007507480A5 (enExample) 2007-11-22
JP4938454B2 true JP4938454B2 (ja) 2012-05-23

Family

ID=29415609

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006530592A Expired - Fee Related JP4938454B2 (ja) 2003-10-07 2004-10-07 止血を促進するためのフィブリノゲン標的微粒子
JP2011143587A Withdrawn JP2011184465A (ja) 2003-10-07 2011-06-28 止血を促進するためのフィブリノゲン標的微粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011143587A Withdrawn JP2011184465A (ja) 2003-10-07 2011-06-28 止血を促進するためのフィブリノゲン標的微粒子

Country Status (9)

Country Link
US (1) US20080064628A1 (enExample)
EP (1) EP1677829B1 (enExample)
JP (2) JP4938454B2 (enExample)
CN (1) CN1863560A (enExample)
AU (1) AU2004280115B2 (enExample)
CA (1) CA2541005C (enExample)
GB (1) GB0323378D0 (enExample)
IL (1) IL174580A0 (enExample)
WO (1) WO2005035002A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US9114127B2 (en) * 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
KR20100057061A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｍａｉｐｐｋｋｎｑｄｋ （소 카파 카세인 １０６－１１６）및／또는 ｙｇｆｑｎａ （세로르핀）의 용도
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
AU2013334180A1 (en) * 2012-10-25 2015-05-14 The Children's Hospital Of Philadelphia Affinity peptide-modified particles and targeted drug delivery methods
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
WO2017103914A1 (en) * 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
EP3887404A4 (en) 2018-11-30 2022-11-02 Cellphire, Inc. SLIDES LOADED WITH ANTI-CANCER AGENTS
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
CA3138529C (en) 2019-05-03 2025-10-07 Cellphire, Inc. MATERIALS AND PROCESSES FOR THE PRODUCTION OF BLOOD PRODUCTS
CN110448719B (zh) * 2019-06-28 2020-05-22 浙江大学 一种促进凝血的丝素-多肽电纺膜及其制备方法
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
EP4416167A4 (en) * 2021-10-15 2025-11-19 Univ North Carolina State COMPOSITIONS AND PROCESSES FOR PURIFYING BIOLOGICAL FLUIDS
US12702682B2 (en) 2021-11-04 2026-08-11 Cellphire, Inc. Platelet derivative compositions, and methods of making and using such compositions
GB2642384A (en) * 2023-01-31 2026-01-07 Univ North Carolina State Compositions and methods for purifying biological fluids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
DE4310632A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
DE69529917T2 (de) * 1994-12-16 2003-12-11 Elan Drug Delivery Ltd., Ruddington Vernetzte mikropartikel und ihre verwendung als arzneiträger
AU718956B2 (en) * 1996-10-21 2000-05-04 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation
GB9724143D0 (en) 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US20030021777A1 (en) * 1998-02-20 2003-01-30 Roy Harris Product comprising bound fibrinogen and thrombin for use in wound therapy or surgical repair
US20040127416A1 (en) 2002-11-15 2004-07-01 Massia Stephen P. Therapeutic bioconjugates

Also Published As

Publication number Publication date
EP1677829A1 (en) 2006-07-12
JP2011184465A (ja) 2011-09-22
IL174580A0 (en) 2006-08-20
AU2004280115A1 (en) 2005-04-21
AU2004280115B2 (en) 2011-03-24
CN1863560A (zh) 2006-11-15
GB0323378D0 (en) 2003-11-05
CA2541005A1 (en) 2005-04-21
EP1677829B1 (en) 2014-12-24
WO2005035002A1 (en) 2005-04-21
CA2541005C (en) 2012-05-08
JP2007507480A (ja) 2007-03-29
US20080064628A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
JP2011184465A (ja) 止血を促進するためのフィブリノゲン標的微粒子
JP2007507480A5 (enExample)
US8105632B2 (en) Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
Satta et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide.
US20130029913A1 (en) Artificial platelets
HU214884B (hu) Vérlemezke membrán mikrorészecskék, ezeket tartalmazó gyógyászati és diagnosztikai készítmények és eljárás a mikrórészecskék és a készítmények előállítására
US9114127B2 (en) Biologic devices for hemostasis
Ghiran et al. Expression and function of C1q receptors and C1q binding proteins at the cell surface
Kitaguchi et al. Characterization of liposomes carrying von Willebrand factor-binding domain of platelet glycoprotein Ibα: A potential substitute for platelet transfusion
JP2008083048A (ja) 凝集能力を有する血小板フラグメントの製造方法及びその使用
US20250073271A1 (en) Methods of administering platelet derivative compositions to reduce bleeding in subjects refractory to platelet transfusion
JP6636443B2 (ja) 出血性症候群の場合における失血を制御する及び／又は血小板の代用にすることが可能であるコラーゲンに基づいた注射用製剤
Zou et al. Multi-functional platelets: translating biological functions into therapeutic applications
Lee et al. Platelet substitutes and novel platelet products
Gordz et al. Effect of desmopressin (DDAVP) on platelet membrane glycoprotein expression in patients with von Willebrand's disease
Sloand et al. Platelet membrane glycoproteins and microvesicles in blood from postoperative salvage: a study in cardiac bypass patients
Sloand et al. DDAVP corrects the platelet dysfunction produced by cardiopulmonary by-pass, hemodialysis, and prolonged storage: Re-expression of glycoprotein Ib on the platelet membrane
Bauer et al. Blood, plasma proteins, coagulation, fibrinolysis, and thrombocyte function
CN110799199A (zh) Rmp组合物及使用方法
BY-PASS EM Sloand¹, CM Kessler², J. Sloand³, and K. Prodouz'National Heart, Lung, and Blood Institute

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110527

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120223

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150302

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4938454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees